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Abstract
Purpose Sorafenib, a multikinase inhibitor of Raf and
several growth factor receptors, is under investigation in
combination with dacarbazine, a commonly used chemo-
therapeutic agent for the treatment of many cancers. The
current phase I study investigates the eVects of sorafenib on
the pharmacokinetic (PK) proWle of dacarbazine and its
metabolite 5-amino-imidazole-4-carboxamide (AIC). (AIC
is formed in amounts equimolar to the active alkylating
moiety, methane diazohydroxide, which is undetectable by
known validated assays.)
Methods Patients with advanced solid tumors received
intravenous dacarbazine 1,000 mg/m2 on day 1 of a 21-day
cycle to evaluate the PK of dacarbazine alone. Sorafenib
400 mg was administered twice daily continuously starting
at day 2 of cycle 1. The PK of dacarbazine in the presence
of sorafenib was assessed on day 1 of cycle 2. Sorafenib PK
was also assessed at steady state.
Results PK data were available for 15 of 23 patients. With
concomitant administration of sorafenib, the mean AUC
and Cmax values of dacarbazine were reduced by 23 and
16%, respectively. Mean AUC and Cmax values of AIC
were increased by 41 and 45%, respectively, with individ-
ual increases of up to 106 and 136%, respectively. The
apparent terminal half-lives of the two compounds were not
signiWcantly inXuenced by sorafenib. Based on coeYcients
of variation, the AUC and Cmax values for sorafenib and its
three metabolites were highly variable with dacarbazine
coadministration.
Conclusions Concomitant administration of sorafenib and
dacarbazine as described above may result in decreased
dacarbazine exposure but increased AIC exposure.
Keywords Sorafenib · Dacarbazine · AIC · 
Pharmacokinetics · Phase I
Introduction
Sorafenib is a multikinase inhibitor of Raf, vascular endo-
thelial growth factor (VEGF) receptors, and platelet-
derived growth factor receptors [1, 2]. It has been approved
as a single agent by the US Food and Drug Administration
(FDA) and the European Medicines Agency (EMA) for the
treatment of advanced renal cell carcinoma and unresec-
table hepatocellular carcinoma. In addition, sorafenib is
being tested in combination with other agents in a variety of
advanced solid tumors such as melanoma, breast cancer,
renal cell carcinoma, hepatic cancer, and non-small-cell
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lung cancer [3–16]. Dacarbazine is the most commonly
used FDA- and EMA-approved chemotherapeutic agent for
the treatment of advanced melanoma. Dacarbazine is
metabolized by various cytochrome P450 (CYP) isoen-
zymes such as CYP1A2, CYP1A1, and CYP2E1 [17].
Sorafenib is primarily metabolized in the liver by CYP3A4
[18]. Therefore, concomitant sorafenib administration is
not expected to aVect dacarbazine metabolism, and the like-
lihood of a pharmacokinetic (PK) drug–drug interaction
between sorafenib and dacarbazine is low.
An earlier phase I study estimated that the maximum-tol-
erated dose of sorafenib in combination with dacarbazine
1,000 mg/m2 was 400 mg twice daily (the standard single-
agent doses for each agent) [19]. The primary objective of
this study was to evaluate the PK proWles of dacarbazine
with and without concomitant sorafenib under steady state
conditions. A secondary objective was to determine the
steady-state PK proWles of sorafenib and its metabolites
BAY 67-3472 (M2), BAY 43-9007 (M4), and BAY 68-
7769 (M5) in the presence of dacarbazine. This paper
reports on PK and safety data. A separate manuscript (in
preparation) [20] reports on eYcacy and functional analysis
using dynamic contrast-enhanced ultrasonography
(DCE-US) representing the blood volume and microarray
analyses of gene expression obtained in sequential tumor
biopsies.
Patients and methods
Patients
Patients with metastatic, histologically conWrmed solid
tumors were included in this study. Eligible patients had at
least one lesion that could be accurately and serially mea-
sured per Response Evaluation Criteria in Solid Tumors
(RECIST) guidelines [21], were ¸18 years of age with an
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of 0 or 1, had adequate bone marrow, liver,
and renal functions, and had a life expectancy of at least
12 weeks. Patients were excluded if they had previous or
concurrent cancer that was distinct from the tumor being
evaluated in this study, unless the other cancer was
curatively treated more than 3 years prior to study entry;
clinically evident congestive heart failure; cardiac
arrhythmias; active coronary heart disease or ischemia;
uncontrolled hypertension; active clinically serious infec-
tions; or active brain metastases. Anticancer chemother-
apy, immunotherapy, or vaccine therapy was not
permitted during or within 30 days prior to the start of
study treatment. Prior treatment with inhibitors of Raf,
VEGF, or mTOR signaling pathways or farnesyl transfer-
ase inhibitors was not permitted.
Study design
This phase I, single-center, open-label, uncontrolled study
was conducted in France between September 2005 (date of
Wrst patient Wrst visit) and August 2006 (data cutoV date).
On day 1 of a 21-day cycle, dacarbazine 1,000 mg/m2 was
administered as a 1-h infusion. Sorafenib 400 mg was
administered twice daily continuously starting on day 2 of
cycle 1. Toxicity-related dose modiWcations of sorafenib
and dacarbazine were performed in accordance with proto-
col-speciWed guidelines. Treatment continued until the
occurrence of unacceptable toxicity, tumor progression, or
death. Sorafenib tablets were supplied by Bayer HealthCare
AG (Leverkusen, Germany); dacarbazine was supplied by
Faulding Pharmaceuticals SA (Asnieres, France). The
study was conducted in accordance with the Declaration of
Helsinki, the International Conference on Harmonization
Good Clinical Practice guidelines, the EU-Directive 2001/
20/EC, and local applicable laws. All patients provided
signed informed consent before starting study treatment.
Study outcomes
The primary endpoint was the determination of the PK pro-
Wle of dacarbazine with and without sorafenib. Secondary
endpoints included evaluation of the PK proWle of sorafenib
in the presence of dacarbazine, safety and eYcacy of the
combination treatment, novel biomarker analyses using
DCE-US, and gene proWle analyses. This paper reports on
PK and safety data; the other results are reported in a sepa-
rate manuscript (in preparation) [20].
Pharmacokinetic variables and sampling schedules
Dacarbazine is a prodrug from which the active alkylat-
ing moiety methane diazohydroxide is formed by metab-
olization. In this metabolic process, the inactive
metabolite 5-amino-imidazole-4-carboxamide (AIC) is
formed in equimolar quantities as methane diazohydrox-
ide, which cannot be analytically measured [17]. There-
fore, in addition to the PK of dacarbazine, we also
studied the PK of AIC to understand the changes in the
exposure of the active alkylating moiety in the presence
of sorafenib.
On day 1 of cycle 1, plasma samples were obtained
prior to dacarbazine administration and at 0.5, 1.0, 1.25,
1.5, 2.0, 4.0, 8.0, 12.0, and 24.0 h following dacarbazine
administration to assess the PK of dacarbazine and AIC in
the absence of sorafenib. On day 1 of cycle 2, samples
were collected from the same patients to assess the PK of
dacarbazine in the presence of sorafenib at the same time
points as above. Additional samples were collected on day
1 of cycle 2 prior to sorafenib dosing and at 0.5, 1.0, 2.0,Cancer Chemother Pharmacol (2011) 68:53–61 55
123
4.0, 8.0, 10.0, and 12.0 h thereafter to evaluate the PK
proWle of sorafenib and its main metabolites, M2, M4, and
M5, in the presence of dacarbazine. Samples for dacarba-
zine measurements were stored at or below ¡70°C; sam-
ples for sorafenib measurements were stored below
¡15°C. Stability data indicated that all analytes were sta-
ble during analysis.
The following PK variables were determined for dacar-
bazine and AIC on day 1 of cycle 1 and day 1 of cycle 2:
area under the plasma concentration–time curve (AUC)
from zero to inWnity after a single dose [AUC(0–inf)], AUC
from time zero to the last data point [AUC(0–tn)], maxi-
mum concentration of drug in plasma (Cmax), time to reach
maximum drug concentration in plasma (tmax), and apparent
terminal half-life (t1/2). The following variables were deter-
mined for sorafenib, M2, M4, and M5 on day 1 of cycle 2:
AUC from time 0–12 h after dose at steady state
[AUC(0–12)ss], AUC(0–12)ss normalized with respect to
Table 1 Patient baseline 
characteristics
Characteristics Patients included 
in the PK analysis (n = 15)
Patients included in the
safety analysis (n = 23)
Sex, n (%)
Male 10 (67) 11 (48)
Female 5 (33) 12 (52)
Age at enrollment, mean § SDa (year) 59.3 § 7.5 57.2 § 8.9
Primary cancer type, n (%)
Malignant melanoma 4 (27) 4 (17)
Leiomyosarcoma 3 (20) 4 (17)
Adenocarcinoma 2 (13) 5 (22)
Neuroendocrine carcinoma 2 (13) 2 (9)
Carcinoid tumor 1 (7) 1 (4)
Epithelioid mesothelioma 1 (7) 3 (13)
Hemangiopericytoma 1 (7) 1 (4)
Hepatocarcinoma 1 (7) 1 (4)
Nesidioblastoma 0 1 (4)
Sarcoma 0 1 (4)
AJCCb stage at study entry, n (%)
Stage IV 14 (93) 22 (96)
Unknown 1 (7) 1 (4)
ECOG performance status, n (%)
0 6 (40) 10 (44)
1 8 (53) 12 (52)
Missing 1 (7) 1 (4)
Prior anticancer therapy, n (%)
Systemic adjuvant therapy
Antineoplastic agents 3 (20) 5 (22)
Immunostimulants 1 (7) 1 (4)
Systemic palliative therapy
Antineoplastic agents 11 (73) 19 (83)
Endocrine therapy 1 (7) 3 (13)
Other 1 (7) 2 (9)
Radiotherapy 6 (40) 10 (43)
Prior anticancer regimens, n (%)
01  ( 7 ) 1  ( 4 )
1 7 (47) 10 (44)
¸2 7 (47) 12 (52)
Time since initial diagnosis, mean § SDa (week)
Malignant melanoma 141.2 § 145.0 141.2 § 145.0
Other tumor types 245.4 § 331.7 197.9 § 261.3
a Standard deviation
b American Joint Committee on 
Cancer56 Cancer Chemother Pharmacol (2011) 68:53–61
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dose (in mg) per kg body weight [AUC(0–12)ss,norm], Cmax
at steady state (Cmax,ss), Cmax,ss normalized with respect to
dose (in mg) per kg body weight (Cmax,ss,norm), and tmax at
steady state (tmax,ss).
Pharmacokinetic assay methods and analyses
All analytes in plasma samples were quantiWed using a
fully validated liquid chromatography–tandem mass
Fig. 1 a Plasma concentrations 
(geometric means/geometric 
standard deviation) of dacarba-
zine after a 1-h intravenous 
infusion of 1,000 mg/m2 dacar-
bazine without (cycle 1) or with 
(cycle 2) concomitant multiple 
oral doses of 400 mg bid sorafe-
nib (n = 15) b Plasma concentra-
tions (geometric means/
geometric standard deviation) of 
AIC after a 1-h intravenous infu-
sion of 1,000 mg/m2 dacarba-
zine without (cycle 1) or with 
(cycle 2) concomitant multiple 
oral doses of 400 mg bid sorafe-
nib (n = 15) c Plasma concentra-
tions (geometric means/
geometric standard deviation) of 
sorafenib after multiple oral dos-
es of 400 mg bid sorafenib and 
following a concomitant 1-h 
intravenous infusion of 
1,000 mg/m2 dacarbazine on day 
1 of cycle 2 (n = 15)Cancer Chemother Pharmacol (2011) 68:53–61 57
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spectrometry assay method with a lower limit of quantiWca-
tion of 40.6 g/l for dacarbazine, 40.7 g/l for AIC, and
0.01 mg/l for sorafenib and its metabolites. The assay for
each sample set was performed once. Mean inter-assay pre-
cision ranges as determined by analysis of quality control
samples were 7.0–8.7% for dacarbazine, 2.8–9.3% for AIC,
1.5–12.4% for sorafenib, 2.6–4.5% for M2, 3.9–5.2% for M4,
and 3.2–6.7% for M5. Corresponding mean inter-assay accu-
racy ranges were 97.1–104.7% for dacarbazine, 99.3–105.3%
for AIC, 102.3–107.0% for sorafenib, 97.9–103.2% for M2,
98.1–100.3% for M4, and 95.5–101.0% for M5. The parame-
ters AUC, AUC(0–tn), and Cmax of dacarbazine and AIC were
analyzed after logarithmic transformations applying an analy-
sis of variance assuming a log-normal distribution.
Table 2 PK data for dacarbazine and AIC after a 1-h intravenous infusion of 1,000 mg/m2 dacarbazine without (day 1, cycle 1) or with (day 2,
cycle 2) administration of concomitant multiple oral doses of 400 mg bid sorafenib (n = 15)
a Geometric mean
b CoeYcient of variation
c ConWdence interval
Parameters Dacarbazine AIC
Cycle 1 Cycle 2 Cycle 2/cycle 1 Cycle 1 Cycle 2 Cycle 2/cycle 1
AUC(0–inf) (mg h/l)
GMa (%CVb) 65.0 (31) 50.0 (36) 20.6 (35) 28.9 (26)
Range 29.4–111.5 24.5–87.8 11.3–33.2 21.8–56.0
Ratio (90% CIc) 0.769 (0.629–0.941) 1.408 (1.167–1.699)
AUC(0–tn) (mg h/l)
GMa (%CVb) 62.9 (29) 49.0 (35) 19.1 (35) 27.1 (25)
Range 29.0–105.3 23.8–84.3 10.5–29.7 19.8–50.4
Cmax (mg/l)
GMa (%CVb) 28.9 (26) 24.4 (26) 4.96 (39) 7.16 (26)
Range 14.4–45.3 13.6–35.8 2.30–9.29 4.18–10.20
Ratio (90% CIc) 0.843 (0.718–0.990) 1.445 (1.184–1.765)
t1/2 (h)
GMa (%CVb) 1.87 (29) 1.72 (22) 2.27 (27) 2.17 (26)
Range 1.34–3.76 1.31–2.87 1.30–3.73 1.50–3.21
tmax (h)
Median 1.00 1.00 1.17 1.17
Range 0.50–1.08 0.50–1.17 0.50–1.58 1.00–2.00
Table 3 PK parameters of 
sorafenib and its metabolites 
BAY-67 3472 (M2), BAY 43-
9007 (M4), and BAY 68-7769 
(M5) after multiple oral doses of 
400 mg bid sorafenib and fol-
lowing a concomitant 1-h intra-
venous infusion of 1,000 mg/m2 
dacarbazine on day 1 of cycle 2
Parameters Sorafenib (n = 15)a M2 (n = 15)a M4 (n = 15)b M5 (n = 13)c
AUC(0–12)ss (mg h/l)
GMd (%CVe) 28.3 (84) 3.01 (207) 1.46 (202) 1.17 (225)
Range 6.13–85.7 0.195–17.6 0.176–14.0 0.218–9.31
AUC(0–12)ss,norm (kg h/l)
GMd (%CVe) 4.75 (93) 0.489 (228) 0.254 (207) 0.200 (238)
Range 0.934–16.1 0.029–3.15 0.026–2.23 0.024–1.44
Cmax,ss (mg/l)
GMd (%CVe) 3.67 (77) 0.371 (197) 0.149 (237) 0.137 (225)
Range 0.905–9.66 0.035–2.03 0.016–1.48 0.022–0.943
Cmax,ss,norm (kg/l)
GMd (%CVe) 0.620 (84) 0.061 (211) 0.026 (244) 0.023 (245)
Range 0.155–1.81 0.005–0.367 0.003–0.236 0.002–0.146
tmax,ss (h)
Median (range) 8.3 (0.5–12.0) 4.0 (0–12.0) 8.3 (0.5–12.0) 4.0 (0–12.0)
a n = 14 for AUC(0–12)ss and 
AUC(0–12)ss,norm
b n = 13 for AUC(0–12)ss and 
AUC(0–12)ss,norm
c n = 12 for AUC(0–12)ss and 
AUC(0–12)ss,norm
d Geometric mean
e CoeYcient of variation58 Cancer Chemother Pharmacol (2011) 68:53–61
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Safety
Safety was evaluated in all patients who had received at
least one dose of either study treatment. Safety was
assessed through observed adverse events (AEs) and results
of physical examination, laboratory tests, and vital signs
measurement. Safety assessment took place at baseline and
weekly starting from day 1 of cycle 1. AEs were coded and
graded using version 3.0 of the National Cancer Institute
Common Toxicity Criteria.
Determination of sample size
As this was a descriptive PK and safety phase I study, no
formal sample size estimation was performed. The planned
enrollment of approximately 25 patients was based on the
requirements of relevant PK data sampling in a phase I
trial.
Results
The study enrolled 24 patients, one of whom developed
progressive disease before study treatment. The remaining
23 patients underwent treatment and were evaluable for
safety analysis. Twenty-one patients (91%) discontinued
treatment owing to progressive disease and two patients
(9%) discontinued owing to AEs. Complete PK data were
available for 15 patients. The other 8 patients had incom-
plete or no PK data on sorafenib and/or dacarbazine and
were not included in the PK evaluation. The baseline
characteristics of patients are reported in Table 1. Detailed
dosing and drug exposure data are reported in the supple-
mentary table.
Pharmacokinetics
The 15 patients included in the PK analysis did not undergo
any dose modiWcations during the PK evaluation period.
For 13 of the 15 patients, the PK proWle of dacarbazine was
determined on day 1 of cycle 1 in the absence of sorafenib
and repeated on day 1 of cycle 2 following a 20-day treat-
ment period of sorafenib, as planned. For two patients, the
second dacarbazine PK sampling was done on day 1 of
cycle 3 and day 1 of cycle 6. For all the PK analyses, these
were combined with data obtained from other patients on
day 1 of cycle 2. Sorafenib PK sampling was performed in
all patients during the second dacarbazine PK sampling.
Geometric mean plasma concentration–time data for
dacarbazine, AIC, and sorafenib are shown in Fig. 1a–c,
respectively. While plasma concentrations of dacarbazine
were slightly lower in cycle 2 at 4 h after start of infusion
and following times when compared with those in cycle 1,
the corresponding mean plasma concentrations of AIC were
distinctly higher in cycle 2 compared with cycle 1. The
apparent t1/2 of either dacarbazine or AIC was not altered on
concomitant administration of sorafenib. Mean plasma con-
centrations of sorafenib ranged between 1.7 and 3.0 mg/l.
Table 2 summarizes the PK results for dacarbazine and
AIC. While the mean AUC and Cmax of dacarbazine were
reduced by 23 and 16%, respectively, mean AUC and Cmax
of AIC were increased by 41 and 45%, respectively, with
individual increases of up to 106 and 136%, respectively.
The apparent t1/2 of either compound was not signiWcantly
inXuenced by concomitant administration of sorafenib.
Table 3 reports the steady state PK data for sorafenib and
its metabolites. Sorafenib contributes approximately 83%
to the sum of AUC(0–12)ss values, while the metabolites
contribute approximately 9% (M2), 4% (M4), and 3%
(M5). From the values of the coeYcients of variation, it is
Table 4 Incidence of drug-related treatment-emergent AEs associ-
ated with dacarbazine, sorafenib, or both, and aVecting at least two
patients
a Worst grade
Total incidence, n (%) (n = 23)
All grades Grade 3a Grade 4a
Blood/bone marrow
Hemoglobin 5 (22) 5 (22) 0
Lymphopenia 2 (9) 2 (9) 0
Neutrophils 5 (22) 3 (13) 2 (9)
Platelets 7 (30) 1 (4) 4 (17)
Constitutional symptoms
Fatigue 17 (74) 4 (17) 0
Fever 7 (30) 0 0
Weight loss 2 (9) 0 0
Dermatology/skin
Alopecia 8 (35) 0 0
Hand-foot skin reaction 11 (48) 1 (4) 0
Pruritus 5 (22) 0 0
Rash/desquamation 11 (48) 2 (9) 0
Gastrointestinal
Anorexia 11 (48) 1 (4) 0
Constipation 3 (13) 0 0
Diarrhea 11 (48) 0 0
Mucositis (symptomatic) 2 (9) 0 0
Nausea 15 (65) 1 (4) 0
Taste alteration 2 (9) 0 0
Vomiting 10 (44) 2 (9) 0
Metabolic/laboratory
Amylase 4 (17) 4 (17) 0
Lipase 5 (22) 2 (9) 3 (13)
Pain
Headache 2 (8) 0 0Cancer Chemother Pharmacol (2011) 68:53–61 59
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evident that the PK parameters of sorafenib and its metabo-
lites showed a high degree of variability.
Safety
Overall, toxicities were manageable, with the vast majority
of grade 3/4 AEs improving or resolving upon transient
study drug dose reduction or discontinuation. No patient
died of treatment-related causes; 10 patients (43.5%) died
of progressive disease, 5 within 30 days after the last dose
of a study drug and 5 thereafter.
Table 4 summarizes the incidence of treatment-emergent
AEs related to one or both of the study drugs and aVecting
at least two patients. The most common grade 3/4 toxicities
included amylase or lipase elevation, which was attributed
to sorafenib and asymptomatic in all cases. The hemato-
logic toxicities were attributed to both study drugs. The
most common drug-related toxicities of any grade were
fatigue, nausea, diarrhea, hand–foot skin reaction, and rash/
desquamation, each aVecting a minimum of just under half
of the patients. The most common categories of toxicities
of any grade were gastrointestinal (19 patients [83%]),
constitutional (18 patients [78%]), and dermatologic (15
patients [65%]).
In Table 5, we report selected PK parameters of AIC in
each of the 15 patients included in the PK analysis and the
associated percent changes in hematologic parameters (i.e.
platelet, leukocyte, and neutrophil levels). It can be seen
that four patients (reference numbers 01, 06, 11, and 14)
with grade 4 platelets and grade 3/4 neutrophils showed an
increase in Cmax and AUC(0–inf) of AIC on concomitant
sorafenib administration. However, we also see an
increased incidence of hematologic toxicities without an
associated increase in the Cmax and AUC(0–inf) on con-
comitant administration of sorafenib (patients with refer-
ence numbers 12 and 13) as well as an increase in Cmax and
AUC(0–inf) without an associated increase in hematologic
toxicities (patient with reference number 09).
Discussion
In this paper, we report PK and safety data from the combi-
nation of sorafenib and dacarbazine in patients with
advanced solid tumors. Our results indicate that while con-
comitant administration of sorafenib and dacarbazine
decreased dacarbazine exposure, it resulted in increased
AIC exposure. We also found that increased AIC exposure
might be associated with an increased incidence of hemato-
logic toxicities, likely because of the interference of meth-
ane diazohydroxide with erythropoiesis [22–24]. However,
because of the small sample size, no statistically signiWcant
Table 5 Individual patient parameters of AIC after a 1-h infusion of
1,000 mg/m2 dacarbazine without (cycle 1) or with (cycle 2) concom-
itant administration of multiple oral doses of 400 mg sorafenib bid and
percent changes in hematologic parameters in patients valid for PK
analysis (n = 15)
a National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0
b Data from cycle 3
c Data from cycle 6
Reference # Cmax (mg/l) AUC(0–inf) (mg h/l) Percent change from baseline 
(NCI CTCAE v3.0a grade)
C1; C2 C2/C1 C1; C2 C2/C1 Platelets Leukocytes Neutrophils
01 4.23; 7.22a 1.70 14.5; 27.2b 1.87 ¡89.3 (G4) ¡70.4 (G3) ¡74.9 (G3)
03 9.29; 10.23 1.10 30.9; 33.9 1.10 ¡41.1 (G1) ¡44.9 (G1) ¡57.0
05 6.36; 7.44 1.17 23.7; 27.3 1.15 ¡72.8 (G1) ¡75.2 (G2) ¡81.2 (G2)
06 2.30; 5.43 2.36 11.3; 23.4 2.06 ¡96.6 (G4) ¡94.9 (G4) ¡97.2 (G4)
07 3.21; 4.18 1.30 15.2; 26.0 1.71 ¡24.7 (G1) ¡36.8 (G1) ¡46.5
09 3.94; 7.77 1.97 16.2; 31.0 1.92 ¡24.4 (G1) ¡35.8 ¡37.0
11 3.87; 6.76 1.75 13.5; 21.9 1.62 ¡88.9 (G4) ¡63.7 (G2) ¡80.0 (G3)
12 6.05; 8.67 1.43 29.0; 39.8 1.37 ¡71.3 (G1) ¡72.1 (G3) ¡83.7 (G3)
13 5.48; 5.89 1.08 21.8; 28.7 1.31 ¡73.3 (G2) ¡74.0 (G3) ¡85.4 (G3)
14 5.32; 9.78 1.84 33.2; 56.0 1.68 ¡95.0 (G4) ¡90.5 (G4) ¡98.3 (G4)
15 7.55; 9.54 1.26 27.2; 32.7 1.20 ¡50.4 (G1) ¡55.4 (G2) ¡55.6 (G2)
17 5.40; 6.84 1.27 21.4; 24.9 1.16 ¡52.9 (G1) ¡37.9 ¡42.6
22 7.88; 9.07 1.15 24.6; 22.5 0.91 ¡85.0 (G2) ¡66.7 (G3) ¡65.8 (G2)
23 4.97; 6.53 1.32 27.8; 31.7 1.14 ¡83.2 (G1) ¡70.1 (G2) ¡77.3 (G1)
24 3.37; 5.29c 1.57 14.7; 21.8b 1.49 ¡13.7 ¡15.9 ¡40.660 Cancer Chemother Pharmacol (2011) 68:53–61
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correlations between increased AIC exposure and hemato-
logic toxicities could be established. Because of the study
design, we could obtain PK proWles of sorafenib and its
metabolites only in the presence of dacarbazine. Similar to
other studies, we found that the PK parameters of sorafenib
and its metabolites showed a high degree of variability
[25]. Our data also show that sorafenib contributes approxi-
mately 83% to the sum of AUC(0–12)ss values, while the
metabolites contribute approximately 9% (M2), 4% (M4),
and 3% (M5). This is comparable with data obtained from
previous single-agent studies (data on Wle, Bayer Health-
Care AG).
The combination of sorafenib and dacarbazine was asso-
ciated with a clinically acceptable toxicity proWle, with the
vast majority of the grades 3/4 AEs improving or resolving
upon transient discontinuation and/or dose reduction of the
study drugs. No unexpected serious adverse reactions were
reported. The sorafenib–dacarbazine combination has also
been investigated in randomized [14] and open-label [26]
phase II studies, and in another phase I study [19] with sim-
ilar safety results. Currently, the combination is being
investigated in a phase II trial for sarcoma (Clinicaltri-
als.gov identiWer: NCT00837148).
In conclusion, the combined treatment with sorafenib
and dacarbazine may result in an increased exposure to
AIC, which may be considered an indicator for the expo-
sure to the active alkylating agent methane diazohydroxide.
Due to the small number of patients in the present study, a
statistically signiWcant correlation between AIC exposure
and observed hematologic toxicities, even if present, could
not be established. Further studies may be necessary to
more clearly characterize this potential drug–drug interac-
tion.
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